Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $106.78M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 0.04M
CLLS Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Cellectis S.A.NASDAQ: CLLS
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -467.4%
Operating margin was -467.4% in Q1 FY2026, down 334.3 pp from a year earlier. On a trailing-twelve-month basis it was -67.6%, up 43.4 pp year over year. Over 3 fiscal years it widened by 422.4 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 3 analysts of -285.5% for the fiscal year ending Dec 2026, down from -45.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -467.4%-300.5 pp QoQ
- Last fiscal yearDec 2025
- -45.3%+98.1 pp YoY
- LTMMar 2026
- -67.6%+43.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -45.3%
- Year-over-year change
- +98.1pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -45.3% | +98.1pp |
| FY2024 | 2024-12-31 | -143.5% | +12744.2pp |
| FY2023 | 2023-12-31 | -12887.7% | -12420.0pp |
| FY2022 | 2022-12-31 | -467.7% | -126.7pp |
| FY2021 | 2021-12-31 | -341.0% | — |
Operating Margin vs competitors
How CLLS compares with its peers on the latest reported figures
- CLLS's LTM Mar 2026 operating margin of -67.6% is the 2nd highest of the 6 companies compared; the peer median is -2154.0%.
- Its year-over-year change of +43.4 pp is the highest of 4, against a peer median of -173.6 pp.
- Over three fiscal years its change of +422.4 pp compares with a peer median of -126.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -17.4% | +27.0 pp | +22.2 pp | |
| LTM Mar 2026 | -67.6% | +43.4 pp | +422.4 pp | |
| LTM Mar 2026 | -1749.0% | -1566.4 pp | -126.9 pp | |
| LTM Mar 2026 | -2154.0% | -173.6 pp | — | |
| LTM Mar 2026 | -7531.1% | — | — | |
| LTM Mar 2026 | -9396.6% | — | -15774.1 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CLLS) | -2154.0% | -173.6 pp | -126.9 pp | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.35M | 19.17M | 755K | 41.51M | 72.95M |
| Cost of Revenue | 1.84M | 8.48M | 7.42M | 9.18M | 9.8M |
| Gross Profit | 28.5M | 10.69M | (6.66M) | 32.32M | 63.15M |
| Gross Margin | 93.9% | 55.7% | -882.6% | 77.9% | 86.6% |
| Research & Development | 117.84M | 97.5M | 87.65M | 90.54M | 93.52M |
| Selling, General & Admin | 22.88M | 8.9M | 8.12M | 8.42M | 8.6M |
| Operating Expenses | 131.98M | 100.35M | 90.64M | 91.88M | 96.23M |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.85M | 20.06M |
| EBITDA | (78.43M) | (76.38M) | (92.64M) | (9.46M) | (39.85M) |
| EBITDA Margin | -258.4% | -398.4% | -12269.8% | -22.8% | -54.6% |
| Operating Income | (103.48M) | (89.67M) | (97.3M) | (59.55M) | (33.08M) |
| Operating Margin | -341.0% | -467.7% | -12887.7% | -143.5% | -45.3% |
| Interest Income | 719K | 1.12M | 3.61M | 11.28M | 9.5M |
| Interest Expense | 4.37M | 3.79M | 5.31M | 7.45M | 8.11M |
| Other Income / Expenses | 6.73M | (8.94M) | (19.16M) | 22.79M | (34.94M) |
| Income Before Tax | (96.75M) | (98.6M) | (116.46M) | (36.76M) | (68.02M) |
| Pre-Tax Margin | -318.8% | -514.3% | -15425.7% | -88.6% | -93.2% |
| Income Tax Expense | (3K) | 87K | 371K | 0 | (423K) |
| Net Income | (114.2M) | (106.14M) | (101.06M) | (36.76M) | (67.59M) |
| Net Margin | -376.3% | -553.6% | -13385.3% | -88.6% | -92.7% |
| EPS (Basic) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| EPS (Diluted) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| Weighted Avg Shares | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
| Weighted Avg Shares (Diluted) | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.